XBiotech Overview
- Founded
-
2005

- Status
-
Public
- Employees
-
94

- Stock Symbol
-
XBIT

- Share Price
-
$5.64
- (As of Friday Closing)
XBiotech General Information
Description
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 5217 Winnebago Lane
- Austin, TX 78744
- United States
+1 (512) 000-0000
XBiotech Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$5.64 | $5.63 | $5.09 - $18.46 | $172M | 30.4M | 142K | -$0.67 |
XBiotech Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 26,012 | 99,467 | 219,498 | 726,545 |
Revenue | 14,044 | 18,394 | 43,997 | 0 |
EBITDA | (26,590) | (23,277) | (13,045) | 720,250 |
Net Income | (20,241) | (17,414) | (11,221) | 668,629 |
Total Assets | 270,803 | 275,177 | 353,744 | 816,877 |
Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
XBiotech Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
XBiotech Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and develop
Biotechnology
Austin, TX
94
As of 2022
0000
0000
0000-00-00
00000000
0000
XBiotech Competitors (90)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland | 000 | 00.000 | 00000000 | 00.000 |
000000000 00000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
00000 | Formerly VC-backed | Cambridge, United Kingdom | 000 | 00000 | 000000&0 | 00000 |
0000 00000000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000 | 00000 |
00000 000000000000 | Formerly VC-backed | London, United Kingdom | 00 | 00000 | 000000000 | 00000 |
XBiotech Patents
XBiotech Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210017257-A1 | Compositions and methods for treating and preventing staphylococcus aureus infections | Pending | 30-Jun-2017 | 00000000000 | |
AU-2015271749-B2 | Compositions and methods for treating and preventing staphylococcus aureus infections | Active | 03-Jun-2014 | 00000000000 | 0 |
CA-2950840-A1 | Compositions and methods for treating and preventing staphylococcus aureus infections | Pending | 03-Jun-2014 | 0000000000 | |
AU-2018200886-B2 | Compositions and methods for treating and preventing staphylococcus aureus infections | Active | 03-Jun-2014 | 00000000000 | 0 |
AU-2018200886-A1 | Compositions and methods for treating and preventing staphylococcus aureus infections | Granted | 03-Jun-2014 | A61K39/395 |
XBiotech Executive Team (6)
XBiotech Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
0000 000000 | XBiotech | Chief Executive Officer & Chairman | 000 0000 |